For a patient with type 1 diabetes currently on insulin glargine (Lantus) 18 U daily, daytime insulin‑sensitivity factor of 25 mg/dL per unit, overnight factor of 50 mg/dL per unit, and insulin‑to‑carbohydrate ratio of 1 U per 8 g, who ate 56 g carbohydrate at 14:00 with a blood glucose of 200 mg/dL at 16:00, then ate 82 g carbohydrate at 19:00 with a blood glucose of 199 mg/dL at 22:00, and had a blood glucose of 132 mg/dL at 04:00, what should the insulin glargine dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Insulin Dose Adjustments for Type 1 Diabetes

Based on your blood glucose pattern showing adequate overnight control (132 mg/dL at 04:00) but persistent daytime hyperglycemia (200 mg/dL at 16:00 and 199 mg/dL at 22:00 despite prandial insulin), you need to increase your prandial insulin doses while keeping your Lantus at 18 units. Your basal insulin is working appropriately, but your insulin-to-carbohydrate ratio needs adjustment.

Analysis of Your Current Pattern

Your overnight glucose dropped from 199 mg/dL at 22:00 to 132 mg/dL at 04:00—a 67 mg/dL decrease over 6 hours. This indicates your basal insulin (Lantus 18 units) is appropriately dosed for overnight control. The problem lies in your daytime prandial coverage.

Meal Coverage Assessment

14:00 meal (56g carbs):

  • Current dose: 56g ÷ 8 = 7 units
  • BG at 16:00: 200 mg/dL (hyperglycemic)
  • This suggests your ICR of 1:8 is insufficient

19:00 meal (82g carbs):

  • Current dose: 82g ÷ 8 = 10.25 units
  • BG at 22:00: 199 mg/dL (still hyperglycemic)
  • Again confirms inadequate prandial coverage

Recommended Adjustments

Lantus Dose: Keep at 18 units

Your basal insulin is working correctly based on the overnight glucose stability. The FDA label recommends that basal insulin should comprise approximately one-third of total daily insulin requirements in type 1 diabetes 1. Your overnight control (132 mg/dL at 04:00 without hypoglycemia) confirms appropriate basal dosing 1.

Insulin-to-Carbohydrate Ratio: Change from 1:8 to 1:6

Your persistent postprandial hyperglycemia (200 mg/dL and 199 mg/dL) despite taking prandial insulin indicates you need more insulin per gram of carbohydrate. Moving from 1:8 to 1:6 represents a 33% increase in prandial insulin, which should address the consistent 70-80 mg/dL elevation above target.

New dosing:

  • 56g meal: 56 ÷ 6 = 9.3 units (round to 9 units)
  • 82g meal: 82 ÷ 6 = 13.7 units (round to 14 units)

Insulin Sensitivity Factor Adjustments

Daytime ISF: Change from 25 to 30 mg/dL per unit

Your current ISF of 25 may be too aggressive. Research suggests that ISF should be approximately 4.5 times your ICR 2. With a new ICR of 1:6, your calculated ISF would be: 6 × 4.5 = 27 mg/dL per unit. Rounding to 30 provides a safer margin to prevent hypoglycemia while still allowing effective correction.

Overnight ISF: Keep at 50 mg/dL per unit

Your overnight control is appropriate, and this more conservative factor helps prevent nocturnal hypoglycemia, which is a critical safety consideration with basal insulin analogues 3.

Implementation Strategy

  1. Make one change at a time: Start with the ICR adjustment to 1:6 for 3-5 days
  2. Monitor closely: Check blood glucose before meals, 2 hours after meals, and at bedtime
  3. Adjust ISF after ICR is stable: Once your postprandial values improve, reassess your correction factor needs
  4. Titrate based on patterns: The 2025 ADA guidelines recommend adjusting insulin every 3 days based on glucose patterns 4

Critical Safety Considerations

Watch for hypoglycemia: With increased prandial insulin, you're at higher risk for low blood glucose. If you experience values <70 mg/dL, reduce the corresponding insulin dose by 10-20% 4.

Avoid stacking corrections: Don't give correction doses within 3-4 hours of your last rapid-acting insulin injection, as insulin-on-board can cause severe hypoglycemia.

Rotate injection sites: Lipohypertrophy can cause erratic insulin absorption and unpredictable glucose control 1.

Why Not Increase Lantus?

Increasing your basal insulin would likely cause nocturnal hypoglycemia. Your 04:00 glucose of 132 mg/dL represents appropriate overnight control. Research demonstrates that titrating basal insulin to morning fasting glucose alone (rather than 24-hour patterns) leads to overbasalization and increased hypoglycemia risk 2. Your daytime hyperglycemia is meal-related, not basal-related, as evidenced by the timing (2-3 hours post-meal).

References

Related Questions

What is the goal dose of Lantus (insulin glargine) for a 115‑lb (≈52‑kg) patient with an A1c of 11% who can no longer use a GLP‑1 receptor agonist?
For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
In a 40‑year‑old man weighing 73 kg with type 1 diabetes, creatinine 1.24 mg/dL, eGFR 75 mL/min, currently on insulin glargine (Lantus) 14 U daily and fixed bolus doses of insulin aspart (Novolog) 18 U at breakfast, 14 U at lunch, and 10 U at dinner, who received dexamethasone 6 mg 24 hours ago and is now started on continuous insulin infusion (CII), what should his insulin glargine (Lantus) dose, insulin‑sensitivity factor (ISF), and insulin‑to‑carbohydrate ratio (ICR) be?
For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
For a 40‑year‑old man weighing 73 kg with type 1 diabetes who is on basal insulin glargine (Lantus) 14 U daily and fixed rapid‑acting insulin (insulin lispro, Novolog) doses of 18 U at breakfast, 14 U at lunch, and 10 U at dinner, and who received dexamethasone 6 mg 24 hours ago requiring an intravenous insulin drip, what should his basal glargine dose, insulin‑to‑carbohydrate ratio (ICR), and insulin sensitivity factor (ISF) be now that he is started on continuous subcutaneous insulin infusion (CSII)?
Can measles reactivate in a patient who is post‑chemotherapy and has recovered from dengue?
What are the contraindications to using hydralazine in a patient with acute intracerebral hemorrhage?
What does a small retrolisthesis at L4‑L5 mean?
What low‑impact core‑strengthening and mobility exercises should a patient with a small L4‑L5 retrolisthesis who is currently asymptomatic perform to prevent future low‑back pain and improve long‑term outcomes?
If a patient starts escitalopram (Lexapro) 10 mg daily in early July, when should the follow‑up visits be scheduled?
What are the causes of functional dyspepsia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.